United States

Dr.Reddy's Laboratories Ltd (REDY.BO)

REDY.BO on Bombay Stock Exchange

24 Mar 2017
Change (% chg)

Rs-8.75 (-0.33%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for REDY.BO


Dr. Reddy's Laboratories Limited is a pharmaceutical company that is engaged in providing medicines. The Company operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment includes manufacturing and marketing prescription and... (more)


Beta: 0.17
Market Cap(Mil.): Rs436,100.09
Shares Outstanding(Mil.): 165.74
Dividend: 20.00
Yield (%): 0.76


  REDY.BO Industry Sector
P/E (TTM): -- 28.94 29.72
EPS (TTM): -- -- --
ROI: -- 13.46 13.00
ROE: -- 14.38 14.15

BRIEF-Cytosorbents Corp enters into a partnership with Dr. Reddy's laboratories

* Have entered into a partnership with Dr. Reddy's laboratories ltd for South African market

Mar 16 2017

BRIEF-Dr.Reddy's Labs gets form 483 with 3 observations from USFDA for audit of Miryalaguda plant

* Says the audit of API manufacturing plant at Miryalaguda, by the US FDA, has been completed on February 21, 2017

Feb 21 2017

BRIEF-Dr.Reddy's Labs says no claims against co for monetary damages

* Clarifies on news item "Dr. Reddy's announces US district court's opinion relating to patent infringement"

Feb 17 2017

BRIEF-Dr Reddy's says U.S. court finds co's product infringes some patents

* Says Dr. Reddy's Laboratories announces U.S. district court's opinion relating to patent infringement

Feb 15 2017

BRIEF-Dr.Reddy's Labs says co not served with legal papers in matter as in Mezzion's press release

* Dr.Reddy's Laboratories clarifies on news item "Korean biotech firm Mezzion Pharma files suit against Dr Reddy's laboratories."

Jan 27 2017

BRIEF-Dr. Reddy's Labs says U.S. FDA re-audit of co's plants part of "usual activity"

* Clarifies on news item "FDA to re-audit three Dr.Reddy's labs plants"

Jan 12 2017

BRIEF-Dr.Reddy's Laboratories announces launch of Raloxifene HCI tablets in the U.S.

* Announces the launch of Raloxifene HCI tablets, USP in the U.S. Market Source text: http://bit.ly/2fHr5V4 Further company coverage:

Nov 11 2016

BRIEF-Sucampo Q3 adjusted EPS $0.28

* Sucampo pharmaceuticals inc - company raises 2016 guidance and provides preliminary 2017 guidance

Nov 09 2016

BRIEF-Dr.Reddy's Labs exec says co has addressed all FDA requirements on warning letters

* Exec says have addressed all FDA requirements on warning letters

Oct 25 2016

BRIEF-Dr.Reddy's Laboratories Sept-qtr consol profit falls 60 pct

* Co to continue to focus on launching new products in generic business

Oct 25 2016

More From Around the Web

Earnings vs. Estimates